Literature DB >> 10759686

Relative contribution of cytochromes P-450 and flavin-containing monoxygenases to the metabolism of albendazole by human liver microsomes.

H C Rawden1, G O Kokwaro, S A Ward, G Edwards.   

Abstract

AIMS: Albendazole (ABZ; methyl 5-propylthio-1H-benzimidazol-2-yl carbamate) is a broad spectrum anthelmintic whose activity resides both in the parent compound and its sulphoxide metabolite (ABS). There are numerous reports of ABZ metabolism in animals but relatively few in humans. We have investigated the sulphoxidation of ABZ in human liver microsomes and recombinant systems.
METHODS: The specific enzymes involved in the sulphoxidation of ABZ were determined by a combination of approaches; inhibition with an antiserum directed against cytochrome P450 reductase, the effect of selective chemical inhibitors on ABZ sulphoxidation in human liver microsomes, the capability of expressed CYP and FMO to mediate the formation of ABS, regression analysis of the rate of metabolism of ABZ to ABS in human liver microsomes against selective P450 substrates and regression analysis of the rate of ABS sulphoxidation against CYP expression measured by Western blotting.
RESULTS: Comparison of Vmax values obtained following heat inactivation (3min at 45 degrees C) of flavin monoxygenases (FMO), chemical inhibition of FMO with methimazole and addition of an antiserum directed against cytochrome P450 reductase indicate that FMO and CYP contribute approximately 30% and 70%, respectively, to ABS production in vitro. Comparison of CLint values suggests CYP is a major contributor in vivo. A significant reduction in ABZ sulphoxidation (n = 3) was seen with ketoconazole (CYP3 A4; 32-37%), ritonavir (CYP3 A4: 34-42%), methimazole (FMO: 28-49%) and thioacetamide (FMO; 32-35%). Additive inhibition with ketoconazole and methimazole was 69 +/- 8% (n = 3). ABS production in heat - treated microsomes (3 min at 45 degrees C) correlated significantly with testosterone 6beta-hydroxylation (CYP3A4; P < 0.05) and band intensities on Western blots probed with an antibody selective for 3A4 (P < 0.05). Recombinant human CYP3 A4, CYP1A2 and FMO3 produced ABS in greater quantities than control microsomes, with those expressing CYP3A4 producing threefold more ABS than those expressing CYP1A2. Kinetic studies showed the Km values obtained with both CYP3A4 and FMO3 were similar.
CONCLUSIONS: We conclude that the production of ABS in human liver is mediated via both FMO and CYP, principally CYP3A4, with the CYP component being the major contributor.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10759686      PMCID: PMC2014938          DOI: 10.1046/j.1365-2125.2000.00170.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  27 in total

1.  THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE.

Authors:  T OMURA; R SATO
Journal:  J Biol Chem       Date:  1964-07       Impact factor: 5.157

2.  Benzimidazoles in a wormy world.

Authors:  R J Horton
Journal:  Parasitol Today       Date:  1990-04

3.  Inducing effect of albendazole on rat liver drug-metabolizing enzymes and metabolite pharmacokinetics.

Authors:  H Souhaili-el Amri; X Fargetton; E Benoit; M Totis; A M Batt
Journal:  Toxicol Appl Pharmacol       Date:  1988-01       Impact factor: 4.219

4.  Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes.

Authors:  D J Newton; R W Wang; A Y Lu
Journal:  Drug Metab Dispos       Date:  1995-01       Impact factor: 3.922

5.  Involvement of P4503A in the metabolism of 7,8-benzoflavone by human liver microsomes.

Authors:  H S Lee; C B Jin; H S Chong; C H Yun; J S Park; D H Kim
Journal:  Xenobiotica       Date:  1994-11       Impact factor: 1.908

Review 6.  Selective inhibitors of cytochromes P450.

Authors:  J R Halpert; F P Guengerich; J R Bend; M A Correia
Journal:  Toxicol Appl Pharmacol       Date:  1994-04       Impact factor: 4.219

7.  Flavin-containing monooxygenase activity in human liver microsomes.

Authors:  M E McManus; I Stupans; W Burgess; J A Koenig; P M Hall; D J Birkett
Journal:  Drug Metab Dispos       Date:  1987 Mar-Apr       Impact factor: 3.922

8.  The metabolism of benzimidazole anthelmintics.

Authors:  D W Gottschall; V J Theodorides; R Wang
Journal:  Parasitol Today       Date:  1990-04

9.  Sulphoxidation of albendazole by the FAD-containing and cytochrome P-450 dependent mono-oxygenases from pig liver microsomes.

Authors:  H S el Amri; X Fargetton; P Delatour; A M Batt
Journal:  Xenobiotica       Date:  1987-10       Impact factor: 1.908

10.  Albendazole sulfonation by rat liver cytochrome P-450c.

Authors:  H Souhaili-El Amri; O Mothe; M Totis; C Masson; A M Batt; P Delatour; G Siest
Journal:  J Pharmacol Exp Ther       Date:  1988-08       Impact factor: 4.030

View more
  20 in total

1.  Effect of ritonavir on the pharmacokinetics of the benzimidazoles albendazole and mebendazole: an interaction study in healthy volunteers.

Authors:  Natascia Corti; Antje Heck; Katharina Rentsch; Walter Zingg; Alexander Jetter; Bruno Stieger; Christiane Pauli-Magnus
Journal:  Eur J Clin Pharmacol       Date:  2009-06-27       Impact factor: 2.953

2.  Albendazole Sulfoxide Plasma Levels and Efficacy of Antiparasitic Treatment in Patients With Parenchymal Neurocysticercosis.

Authors:  Gianfranco Arroyo; Javier A Bustos; Andres G Lescano; Isidro Gonzales; Herbert Saavedra; Silvia Rodriguez; E Javier Pretell; Pierina S Bonato; Vera L Lanchote; Osvaldo M Takayanagui; John Horton; Armando E Gonzalez; Robert H Gilman; Hector H Garcia
Journal:  Clin Infect Dis       Date:  2019-11-13       Impact factor: 9.079

3.  In Vitro and In Vivo Drug Interaction Study of Two Lead Combinations, Oxantel Pamoate plus Albendazole and Albendazole plus Mebendazole, for the Treatment of Soil-Transmitted Helminthiasis.

Authors:  Noemi Cowan; Mireille Vargas; Jennifer Keiser
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

4.  Population Pharmacokinetic Model of Oxfendazole and Metabolites in Healthy Adults following Single Ascending Doses.

Authors:  Thanh Bach; Daryl J Murry; Larissa V Stebounova; Gregory Deye; Patricia Winokur; Guohua An
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

Review 5.  Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism.

Authors:  Sharon K Krueger; David E Williams
Journal:  Pharmacol Ther       Date:  2005-06       Impact factor: 12.310

6.  CYP2J2 and CYP2C19 are the major enzymes responsible for metabolism of albendazole and fenbendazole in human liver microsomes and recombinant P450 assay systems.

Authors:  Zhexue Wu; Doohyun Lee; Jeongmin Joo; Jung-Hoon Shin; Wonku Kang; Sangtaek Oh; Do Yup Lee; Su-Jun Lee; Sung Su Yea; Hye Suk Lee; Taeho Lee; Kwang-Hyeon Liu
Journal:  Antimicrob Agents Chemother       Date:  2013-08-19       Impact factor: 5.191

7.  Plasma disposition and faecal excretion of netobimin metabolites and enantiospecific disposition of albendazole sulphoxide produced in ewes.

Authors:  C Gokbulut; V Y Cirak; B Senlik
Journal:  Vet Res Commun       Date:  2006-10       Impact factor: 2.459

8.  Enantioselective distribution of albendazole metabolites in cerebrospinal fluid of patients with neurocysticercosis.

Authors:  O M Takayanagui; P S Bonato; S A C Dreossi; V L Lanchote
Journal:  Br J Clin Pharmacol       Date:  2002-08       Impact factor: 4.335

9.  Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data.

Authors:  Xue-Qing Li; Anders Björkman; Tommy B Andersson; Lars L Gustafsson; Collen M Masimirembwa
Journal:  Eur J Clin Pharmacol       Date:  2003-08-12       Impact factor: 2.953

10.  Albendazole and its metabolites in the breast milk of lactating women following a single oral dose of albendazole.

Authors:  Ahmed M Abdel-tawab; Mark Bradley; Essam A Ghazaly; John Horton; Maged el-Setouhy
Journal:  Br J Clin Pharmacol       Date:  2009-11       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.